Biotech company Inhibrx Biosciences clinched a unanimous jury verdict in a trade secrets case that wiped out a demand for damages totaling over $450 million in Delaware federal district court.

The U.S. District Court for the District of Delaware concluded on Nov. 1 that Inhibrx, a La Jolla, California-based company founded in 2010, and its co-founder Dr. Brendan Eckelman, also listed as a defendant, did not misappropriate confidential information related to the development of immuno-oncologic antibody treatments for cancer from rival clinical-stage biopharmaceutical company I-Mab. It also determined that the data at issue did not constitute trade secrets.